Oncolytic viruses for genetic therapy of gastrointestinal tumors;Onkolytische viren als innovativer ansatz in der therapie gastrointestinaler tumoren

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 7, 2003, Pages 667-674

  Bitzer, M ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cancer gene therapy; Oncolysis; Replication competent viral vectors; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; ONYX 015; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; DNA MODIFICATION; DRUG SAFETY; GASTROINTESTINAL TUMOR; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1 VECTOR; MASERNVIRUS VECTOR; METASTASIS; MOLECULAR VIROLOGY; NEWCASTLE DISEASE VIRUS VECTOR; REOVIRUS VECTOR; REPLICATION COMPETENT VIRUS VECTOR; REVIEW; VACCINIA VIRUS VECTOR; VESICULAR STOMATITIS VIRUS VECTOR; VIROTHERAPY;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS, PHASE I; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; GENETIC VECTORS; HUMANS; MEASLES VIRUS; MICE; MUTATION; NEWCASTLE DISEASE VIRUS; REOVIRIDAE; SIMPLEXVIRUS; TUMOR CELLS, CULTURED; VACCINIA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION; VIRUSES;

EID: 0042268107     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40543     Document Type: Review

References (70)

1. Lal S, Lauer UM, Wessels JT et al. Suicide Genes: Past, Present, and Future Perspectives. Immunol Today 2000; 21: 48-54
2. Yoon SK, Armentano D, Wands JR et al. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther 2001; 8: 573-579
3. Bilbao R, Bustos M, Alzuguren P et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther 2000; 7: 1824-1832
4. Erbs P, Regulier E, Kintz J et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/ uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822
5. van Dillin IJ, Mulder NH, Vaalburg W et al. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002; 2: 307-322
6. Elliot G, O'Hare P. Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 1997; 88: 223-233
7. Wybranietz WA, Groß CD, Phelan A et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-Cytosine deaminase (CD) fusion gene. Gene Ther 2001; 8: 1654-1664
8. Oess S, Hildt E. Identification of a novel cell permeable peptide derived from the Hepatitis B virus surface antigen. Gene Ther 2000; 7: 750-758
9. Kirn D. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 2001; 8: 89-98
10. Ring CJA. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502
11. Baum C. Replikative Viren in der Krebstherapie. Forum DKG 2002; Sonderheft 1/02: 58
12. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirol 1993; 36: 193-214
13. Southam CM. Present status of oncolytic virus studies. NY Acad Sci 1960; 22: 656-673
14. Bluming AZ, Ziegler JL. Regressin of Burkitt's lymphoma in association with measles infection. Lancet 1971; ii: 105-106
15. Taqi AM, Abdurrahman MB, Yakubu AM et al. Regression of Hodgkin's disease after measles. Lancet 1981; i: 1112
16. Kirn DH. Replicating oncolytic viruses: an overview. Expert Opin Investig Drugs 1996; 5: 753-762
17. Tollefson A, Scaria A, Hermiston TW et al. The adenovirus death protein (E3-11.6K) is required at late stages of infection for efficient lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306
18. Everett H, McFadden G. Apoptosis: an innate immune response to virus infection. Trends in Microbiol 1999; 7: 160-165
19. Basu S, Binder RJ, Suto R et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12: 1539-1546
20. Berwin B, Reed RC, Nicchitta CV. Virally induced lytic cell death elicits the release of immunogenic grp94/gp96. J Biol Chem 2001; 276: 21083-21088
21. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity. J Natl Cancer Institute 1988; 80: 1305-1312
22. Stojdl DF, Lichty B, Knowles S et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine 2000; 6: 821-825
23. Coffey M, Strong J, Forsyth P et al. Reovirus therapy of tumors with activated ras pathway. Science 1998; 282: 1332-1334
24. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-251
25. Strong JE, Coffey MC, Tang D et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 12: 3351-3362
26. Pecora AL, Rizvi NR, Cohen GI et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncology 2002; 20: 2251-2266
27. Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Human Gene Ther 1999; 10: 1721-1733
28. Yamada Y, Takahashi M, Sato Y et al. Augmented apoptosis-inducing gene therapy for HCC by p53 under control of AFP promoter in combination with a selectively replication-competent oncolytic adenovirus and chemotherapeutic agent. Mol Ther 2002; 5: S268
29. Ohguchi S, Nakatsukasa H, Higashi T et al. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology 1998; 27: 599-607
30. Brunori M, Malerba M, Kashiwazaki H et al. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virology 2001; 75: 2857-2865
31. Powell S, Wang Z, Lemos B et al. A conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum anti-tumor activity. Mol Ther 2002; 5: S19
32. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376
33. Biederer C, Ries S, Brandts CH et al. Replication-selective viruses for cancer therapy. J Mol Med 2002; 80: 163-175
34. Ganly I, Kirn D, Eckhardt S. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806
35. Vasey P, Shukman L, Gore M et al. Phase I trial of intraperitoneal ONYX-015 adenovirus in patients with recurrent ovarian carcinoma. Proceedings American Society of Clinical Oncology 2000; 19: 1512
36. Reid T et al. Hepatric artery infusion of ONYX-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestoinal carcinoma metastatic to the liver: A Phase I/II clinical trial. Proceedings American Society of Clinical Oncology 2000; 19: 953
37. Nemunaitis J, Ganly I, Khuri F et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase 11 trial. Cancer Res 2000; 60: 6359-6366
38. Khuri F, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine 2000; 6: 879-885
39. Nemunaitis J, Cunningham C, Buchanan A et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8: 746-759
40. Hecht R et al. A phase I/II trial of intratumoral endoscopic injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Proceedings American Society of Clinical Oncology 2000; 19: 1039
41. Mulvihill S, Warren R, Venook A et al. Safety and feasibility of injection with an ElB-55 kD gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315
42. Yoon SS, Nakamura H, Coroll NM et al. An oncolytic herpes simplex virus type I selectivley destroys diffuse liver metastases from colon carcinoma. FASEB J 2000; 14: 301-311
43. Pawlik TM, Nakamura H, Yoon SS et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-2795
44. DeRubertis BG, Stiles BM, Bhargava A et al. Cytokine secreting oncolytic Herpes Virus effectively treats micrometastatic liver disease in a murine model. Mol Ther 2002; 5: S101-S102
45. Horsburgh BC, Fong Y, Malhotra S et al. Multiple administration of NV1020, an oncolytic HSV-1, results in increased anti-tumor efficacy in rodents with colorectal metastases to liver. Mol Ther 2002; 5: S148
46. Markert J et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malingnant glioma. Results of a phase I trial. Gene Ther 2000; 7: 867-874
47. Mastrangelo M, Eisenlohr L, Gomella L et al. Poxvirus vevtors: Orphaned and underaprreciated. J Clin Invest 2000; 105: 1031-1034
48. Conry RM et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic: Comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5: 2330-2337
49. Hirasawa K, Yoon C, Nishikawa SG et al. Reovirus therapy of metastatic cancer models in immune-competent mice. Proc. Am Assoc Cancer Res 2001; 42: 2437a
50. Aktelle Informationen des National Cancer Institutes zu dem Klinischen Einsatz von NDV finden sich unter folgender Homepage-Adresse: http://www.cancer.gov/cancer_information/doc.aspx?viewid = 284ad06f-682d-43df-bccf-4943a09c1e98.
51. Roberts MS, Buasen PT, Incao BA et al. PV 701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts. Proc Am Assoc Cancer Res 2001; 42: 2441a
52. Phuangsab A, Lorence RM, Reichard KW et al. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Letters 2001; 172: 27-36
53. Bateman A, Bullough F, Murphy S et al. Fusogenic membrane glycoproteins as a novel class of genes for local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497
54. Enders J, Peebles T. Propagation in tissue culture of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 1954; 86: 277-286
55. Grote D, Russell SJ, Corni TI et al. Live attenuated measle virus induces regression of human lymphoma xenografts in immunodeficient mice. Blodd 2001; 97: 3746-3754
56. Peng KW, Facteau S, Wegman T et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nature Medicine 2002; 8: 527-531
57. Peng KW, TenEyck CT, Galanis E et al. Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus. Mol Ther 2002; 5: S444
58. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrrant p53, Ras, or Myc function and involves induction of apoptosis. J Virol 2001; 75: 3474-3479
59. Fernandez M, Porosnicu M, Markovic D et al. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904
60. Weiss RA. Introducing viruses and cancer. In: Arrand JR, Harper DR (Hrsg). Viruses and Human Cancer. Oxford: Bios Scientific Publishers; 1-15
61. Heise C, Williams A, Olesch J et al. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6: 499-504
62. Douglas J, Kim M, Sumerel L et al. Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res 2001; 61: 499-504
63. Yu D et al. Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525
64. Heise C, Lemmon M, Kirn D. Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status. Clin Cancer Res 2000; 6: 4908-4914
65. Sugarbaker PH, Schellinx ME, Chang D et al. Peritonela carcinomatosis from adenocarcinoma of the colon. World J Surgery 1996; 20: 585-592
66. Rogulski KR, Freytag SO, Zhang K et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193-1196
67. Barajas M, Mazzolini G, Genove G et al. Gene therapy of orthotopic hepatocellular carcinomas in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33: 52-61
68. Habib NA, Mitry RR, Sarraf CE et al. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther 2002; 9: 414-420
69. Habib NA, Sarraf CE, Mitry RR et al. E1B deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12: 219-226
70. Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase 1 trial. Gene Ther 2001; 8 (21): 1618-1626